Incyte Corporation (INCY)
USD 58.34
(-3.71%)
USD 58.34
(-3.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 597.59 Million USD | 75.42% |
| 2022 | 340.66 Million USD | -64.09% |
| 2021 | 948.58 Million USD | 420.79% |
| 2020 | -295.69 Million USD | -166.17% |
| 2019 | 446.9 Million USD | 308.16% |
| 2018 | 109.49 Million USD | 134.97% |
| 2017 | -313.14 Million USD | -400.46% |
| 2016 | 104.22 Million USD | 1495.8% |
| 2015 | 6.53 Million USD | 113.47% |
| 2014 | -48.48 Million USD | 41.69% |
| 2013 | -83.14 Million USD | -87.61% |
| 2012 | -44.32 Million USD | 76.24% |
| 2011 | -186.54 Million USD | -485.76% |
| 2010 | -31.84 Million USD | 84.97% |
| 2009 | -211.87 Million USD | -18.42% |
| 2008 | -178.92 Million USD | -105.94% |
| 2007 | -86.88 Million USD | -17.14% |
| 2006 | -74.16 Million USD | 28.02% |
| 2005 | -103.04 Million USD | 37.48% |
| 2004 | -164.81 Million USD | 0.99% |
| 2003 | -166.46 Million USD | -21.61% |
| 2002 | -136.88 Million USD | 25.3% |
| 2001 | -183.23 Million USD | -516.23% |
| 2000 | -29.73 Million USD | -10.95% |
| 1999 | -26.8 Million USD | -865.71% |
| 1998 | 3.5 Million USD | -66.35% |
| 1997 | 10.4 Million USD | 252.94% |
| 1996 | -6.8 Million USD | 32.67% |
| 1995 | -10.1 Million USD | 12.17% |
| 1994 | -11.5 Million USD | -134.69% |
| 1993 | -4.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -444.6 Million USD | -362.23% |
| 2024 Q3 | 106.45 Million USD | 123.94% |
| 2024 Q1 | 169.54 Million USD | -15.68% |
| 2023 Q1 | 21.7 Million USD | -23.74% |
| 2023 FY | 597.59 Million USD | 75.42% |
| 2023 Q4 | 201.07 Million USD | 17.41% |
| 2023 Q2 | 203.54 Million USD | 837.88% |
| 2023 Q3 | 171.26 Million USD | -15.86% |
| 2022 FY | 340.66 Million USD | -64.09% |
| 2022 Q1 | 37.99 Million USD | -93.26% |
| 2022 Q2 | 161.43 Million USD | 324.91% |
| 2022 Q3 | 112.77 Million USD | -30.14% |
| 2022 Q4 | 28.46 Million USD | -74.76% |
| 2021 FY | 948.58 Million USD | 420.79% |
| 2021 Q4 | 563.85 Million USD | 210.25% |
| 2021 Q2 | 149.45 Million USD | 179.17% |
| 2021 Q3 | 181.73 Million USD | 21.6% |
| 2021 Q1 | 53.53 Million USD | -64.27% |
| 2020 Q4 | 149.85 Million USD | 1085.66% |
| 2020 FY | -295.69 Million USD | -166.17% |
| 2020 Q1 | -720.64 Million USD | -749.2% |
| 2020 Q2 | 290.29 Million USD | 140.28% |
| 2020 Q3 | -15.2 Million USD | -105.24% |
| 2019 Q1 | 102.31 Million USD | 48.14% |
| 2019 Q4 | 111 Million USD | -13.46% |
| 2019 FY | 446.9 Million USD | 308.16% |
| 2019 Q3 | 128.27 Million USD | 21.79% |
| 2019 Q2 | 105.31 Million USD | 2.94% |
| 2018 Q4 | 69.06 Million USD | 136.71% |
| 2018 FY | 109.49 Million USD | 134.97% |
| 2018 Q3 | 29.17 Million USD | -44.31% |
| 2018 Q1 | -41.14 Million USD | 72.51% |
| 2018 Q2 | 52.39 Million USD | 227.36% |
| 2017 FY | -313.14 Million USD | -400.46% |
| 2017 Q1 | -187.08 Million USD | -2208.45% |
| 2017 Q2 | -12.48 Million USD | 93.33% |
| 2017 Q3 | 36.05 Million USD | 388.8% |
| 2017 Q4 | -149.62 Million USD | -515.01% |
| 2016 Q3 | 36.87 Million USD | 7.12% |
| 2016 Q2 | 34.42 Million USD | 43.16% |
| 2016 FY | 104.22 Million USD | 1495.8% |
| 2016 Q4 | 8.87 Million USD | -75.94% |
| 2016 Q1 | 24.04 Million USD | -56.42% |
| 2015 Q4 | 55.17 Million USD | 239.4% |
| 2015 Q3 | -39.58 Million USD | -525.89% |
| 2015 Q1 | -18.35 Million USD | 50.31% |
| 2015 FY | 6.53 Million USD | 113.47% |
| 2015 Q2 | 9.29 Million USD | 150.62% |
| 2014 FY | -48.48 Million USD | 41.69% |
| 2014 Q4 | -36.94 Million USD | -162.31% |
| 2014 Q3 | 59.29 Million USD | 260.8% |
| 2014 Q2 | -36.87 Million USD | -8.59% |
| 2014 Q1 | -33.95 Million USD | 20.79% |
| 2013 FY | -83.14 Million USD | -87.61% |
| 2013 Q2 | -2.57 Million USD | 83.59% |
| 2013 Q1 | -15.66 Million USD | -183.44% |
| 2013 Q4 | -42.87 Million USD | -94.54% |
| 2013 Q3 | -22.03 Million USD | -757.14% |
| 2012 FY | -44.32 Million USD | 76.24% |
| 2012 Q2 | 4.03 Million USD | 108.89% |
| 2012 Q1 | -45.42 Million USD | 17.53% |
| 2012 Q4 | 18.77 Million USD | 186.5% |
| 2012 Q3 | -21.71 Million USD | -637.78% |
| 2011 Q3 | -53.07 Million USD | -2.33% |
| 2011 Q1 | -26.51 Million USD | -181.47% |
| 2011 Q4 | -55.07 Million USD | -3.77% |
| 2011 FY | -186.54 Million USD | -485.76% |
| 2011 Q2 | -51.87 Million USD | -95.65% |
| 2010 Q4 | 32.54 Million USD | 202.65% |
| 2010 Q2 | 3.04 Million USD | 108.52% |
| 2010 Q1 | -35.72 Million USD | 59.6% |
| 2010 FY | -31.84 Million USD | 84.97% |
| 2010 Q3 | -31.7 Million USD | -1141.43% |
| 2009 Q2 | -40.03 Million USD | 0.0% |
| 2009 Q4 | -88.44 Million USD | -103.99% |
| 2009 FY | -211.87 Million USD | -18.42% |
| 2009 Q1 | -40.03 Million USD | 17.29% |
| 2009 Q3 | -43.35 Million USD | -8.3% |
| 2008 FY | -178.92 Million USD | -105.94% |
| 2008 Q1 | -40.15 Million USD | -84.2% |
| 2008 Q2 | -45.56 Million USD | -13.46% |
| 2008 Q3 | -44.79 Million USD | 1.69% |
| 2008 Q4 | -48.4 Million USD | -8.06% |
| 2007 Q1 | -22.14 Million USD | -8.02% |
| 2007 Q4 | -21.8 Million USD | 10.99% |
| 2007 Q3 | -24.49 Million USD | -32.84% |
| 2007 Q2 | -18.43 Million USD | 16.74% |
| 2007 FY | -86.88 Million USD | -17.14% |
| 2006 Q2 | -20.52 Million USD | -18.57% |
| 2006 Q3 | -15.83 Million USD | 22.82% |
| 2006 FY | -74.16 Million USD | 28.02% |
| 2006 Q4 | -20.5 Million USD | -29.45% |
| 2006 Q1 | -17.3 Million USD | 37.2% |
| 2005 Q4 | -27.55 Million USD | 8.79% |
| 2005 FY | -103.04 Million USD | 37.48% |
| 2005 Q2 | -25.14 Million USD | -24.91% |
| 2005 Q1 | -20.13 Million USD | 46.35% |
| 2005 Q3 | -30.21 Million USD | -20.14% |
| 2004 Q2 | -63.6 Million USD | -68.63% |
| 2004 Q1 | -37.71 Million USD | 7.49% |
| 2004 FY | -164.81 Million USD | 0.99% |
| 2004 Q3 | -25.97 Million USD | 59.16% |
| 2004 Q4 | -37.52 Million USD | -44.46% |
| 2003 Q1 | -55.78 Million USD | 17.35% |
| 2003 FY | -166.46 Million USD | -21.61% |
| 2003 Q4 | -40.76 Million USD | 5.22% |
| 2003 Q3 | -43.01 Million USD | -59.9% |
| 2003 Q2 | -26.9 Million USD | 51.78% |
| 2002 Q3 | -38.41 Million USD | -118.98% |
| 2002 FY | -136.88 Million USD | 25.3% |
| 2002 Q4 | -67.49 Million USD | -75.71% |
| 2002 Q2 | -17.54 Million USD | -30.5% |
| 2002 Q1 | -13.44 Million USD | 90.74% |
| 2001 Q1 | -10.31 Million USD | -39.92% |
| 2001 Q2 | -9.89 Million USD | 4.08% |
| 2001 Q3 | -17.82 Million USD | -80.23% |
| 2001 Q4 | -145.2 Million USD | -714.52% |
| 2001 FY | -183.23 Million USD | -516.23% |
| 2000 Q1 | -8.17 Million USD | -27.77% |
| 2000 Q3 | -7.59 Million USD | -15.3% |
| 2000 Q4 | -7.37 Million USD | 3.0% |
| 2000 FY | -29.73 Million USD | -10.95% |
| 2000 Q2 | -6.59 Million USD | 19.41% |
| 1999 Q4 | -6.4 Million USD | 42.34% |
| 1999 Q3 | -11.1 Million USD | -50.0% |
| 1999 Q2 | -7.4 Million USD | -289.47% |
| 1999 FY | -26.8 Million USD | -865.71% |
| 1999 Q1 | -1.9 Million USD | -226.67% |
| 1998 Q2 | 5.2 Million USD | 44.44% |
| 1998 Q4 | 1.5 Million USD | 122.06% |
| 1998 Q3 | -6.8 Million USD | -230.77% |
| 1998 Q1 | 3.6 Million USD | -18.18% |
| 1998 FY | 3.5 Million USD | -66.35% |
| 1997 FY | 10.4 Million USD | 252.94% |
| 1997 Q1 | 1 Million USD | 400.0% |
| 1997 Q2 | 1.9 Million USD | 90.0% |
| 1997 Q3 | 3 Million USD | 57.89% |
| 1997 Q4 | 4.4 Million USD | 46.67% |
| 1996 Q2 | -1.6 Million USD | 20.0% |
| 1996 Q3 | -3.4 Million USD | -112.5% |
| 1996 Q4 | 200 Thousand USD | 105.88% |
| 1996 FY | -6.8 Million USD | 32.67% |
| 1996 Q1 | -2 Million USD | 9.09% |
| 1995 Q1 | -2 Million USD | 47.37% |
| 1995 Q4 | -2.2 Million USD | 26.67% |
| 1995 Q3 | -3 Million USD | -3.45% |
| 1995 Q2 | -2.9 Million USD | -45.0% |
| 1995 FY | -10.1 Million USD | 12.17% |
| 1994 Q3 | -3.1 Million USD | -24.0% |
| 1994 Q2 | -2.5 Million USD | -19.05% |
| 1994 FY | -11.5 Million USD | -134.69% |
| 1994 Q1 | -2.1 Million USD | -50.0% |
| 1994 Q4 | -3.8 Million USD | -22.58% |
| 1993 FY | -4.9 Million USD | 0.0% |
| 1993 Q3 | -1.4 Million USD | 0.0% |
| 1993 Q4 | -1.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 508.202% |
| Alkermes plc | 355.75 Million USD | -67.98% |
| Agenus Inc. | -245.76 Million USD | 343.163% |
| Aptorum Group Limited | -2.82 Million USD | 21256.591% |
| Ardelyx, Inc. | -66.06 Million USD | 1004.535% |
| Dyadic International, Inc. | -6.79 Million USD | 8894.091% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 63946.047% |
| Lantern Pharma Inc. | -15.96 Million USD | 3843.995% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 3240.484% |
| Novavax, Inc. | -545.06 Million USD | 209.639% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 1125.164% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 909.864% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 3322.236% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 6084.368% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 1113.177% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 259.944% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 2555.285% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 1700.426% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 463.119% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 914.756% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 3045.143% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 1059.921% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 1939.615% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 551.042% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 235.743% |
| AlloVir, Inc. | -190.41 Million USD | 413.835% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 391.121% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 2200.376% |
| Bicycle Therapeutics plc | -180.66 Million USD | 430.779% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 433.755% |
| ChromaDex Corporation | -4.93 Million USD | 12202.045% |
| Chimerix, Inc. | -82.09 Million USD | 827.936% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 1439.808% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 685.48% |
| CRISPR Therapeutics AG | -153.61 Million USD | 489.037% |
| Precision BioSciences, Inc. | -61.31 Million USD | 1074.574% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 471.346% |
| Fortress Biotech, Inc. | -60.63 Million USD | 1085.535% |
| Fortress Biotech, Inc. | -60.63 Million USD | 1085.535% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 832.531% |
| ImmuCell Corporation | -5.77 Million USD | 10448.755% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 629.031% |
| Immix Biopharma, Inc. | -15.42 Million USD | 3973.96% |
| Innoviva, Inc. | 179.72 Million USD | -232.513% |
| IO Biotech, Inc. | -86.08 Million USD | 794.213% |
| Jaguar Health, Inc. | -41.3 Million USD | 1546.971% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 490.608% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -1045.835% |
| ContextLogic Inc. | -317 Million USD | 288.517% |
| MiMedx Group, Inc. | 67.43 Million USD | -786.133% |
| MEI Pharma, Inc. | 17.77 Million USD | -3261.452% |
| NextCure, Inc. | -62.72 Million USD | 1052.759% |
| Onconetix, Inc. | -37.4 Million USD | 1697.444% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 1613.714% |
| Opthea Limited | -220.24 Million USD | 371.337% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 1268.12% |
| Vaxcyte, Inc. | -402.26 Million USD | 248.558% |
| PDS Biotechnology Corporation | -42.94 Million USD | 1491.636% |
| Precigen, Inc. | -95.9 Million USD | 723.122% |
| Pharming Group N.V. | -10.54 Million USD | 5765.52% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 396.44% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 2534.906% |
| PureTech Health plc | -65.69 Million USD | 1009.629% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 2481.727% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 381.594% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 2555.285% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 331.779% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 2293.99% |
| Acelyrin, Inc. | -381.64 Million USD | 256.587% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 4764620.211% |
| Summit Therapeutics Inc. | -614.92 Million USD | 197.182% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 1852.438% |
| Senti Biosciences, Inc. | -92.91 Million USD | 743.14% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 670.778% |
| Elevation Oncology, Inc. | -45.7 Million USD | 1407.542% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 1800.623% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 4671.643% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 9039.402% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 2135.28% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 7129.749% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 1139.068% |
| Seer, Inc. | -86.27 Million USD | 792.652% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 992.005% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 1008.689% |
| ESSA Pharma Inc. | -26.58 Million USD | 2348.105% |
| GlycoMimetics, Inc. | -36.89 Million USD | 1719.535% |
| GT Biopharma, Inc. | -7.59 Million USD | 7966.25% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 347.596% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 1250.889% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -736.856% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 1198.083% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 1316.61% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 6107.381% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 204.322% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 16755.491% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 1270.432% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 343.327% |
| Aptose Biosciences Inc. | -51.2 Million USD | 1267.026% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 707.947% |
| Soligenix, Inc. | -6.14 Million USD | 9831.726% |
| Century Therapeutics, Inc. | -136.67 Million USD | 537.247% |
| Kura Oncology, Inc. | -152.63 Million USD | 491.532% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 769.819% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 5770.896% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -105581.822% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 105126.186% |
| Autolus Therapeutics plc | -208.38 Million USD | 386.779% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 931.176% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 944.126% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 2857.98% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 365.305% |
| GRI Bio, Inc. | -13.03 Million USD | 4683.869% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 14553.688% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 581.608% |
| IGM Biosciences, Inc. | -246.41 Million USD | 342.516% |
| INmune Bio, Inc. | -30 Million USD | 2091.466% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 640.525% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 1516.32% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 3843.966% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 3883.474% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 1101.255% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 690.705% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 316.423% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 351.206% |
| Verastem, Inc. | -87.36 Million USD | 784.01% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 1202.825% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 470.406% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 612.266% |
| Histogen Inc. | -10.62 Million USD | 5726.579% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 4282.888% |
| Surrozen, Inc. | -43.04 Million USD | 1488.409% |
| Organovo Holdings, Inc. | -14.67 Million USD | 4173.335% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 11847.505% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 1241.786% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 2465.511% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 2318.424% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 7250.806% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 495.538% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 1321.433% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 2110.426% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 5836.379% |
| Apollomics, Inc. | -172.6 Million USD | 446.231% |
| Amarin Corporation plc | -59.11 Million USD | 1110.961% |
| Mesoblast Limited | -87.95 Million USD | 779.429% |
| Turnstone Biologics Corp. | -55.2 Million USD | 1182.607% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 506.635% |
| Synaptogenix, Inc. | -6.03 Million USD | 9996.474% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 3787.062% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 865.956% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 12572.154% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 7212.414% |
| Exelixis, Inc. | 207.76 Million USD | -187.632% |
| Better Therapeutics, Inc. | -39.76 Million USD | 1603.016% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 515.149% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 213.047% |
| NLS Pharmaceutics AG | -12.17 Million USD | 5009.609% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 7766.745% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 2043.475% |
| Gritstone bio, Inc. | -138.49 Million USD | 531.511% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 1027.013% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 15040.162% |
| Avid Bioservices, Inc. | -140.75 Million USD | 524.573% |
| Insmed Incorporated | -749.56 Million USD | 179.726% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 4034.288% |
| MediWound Ltd. | -6.71 Million USD | 8998.139% |
| OmniAb, Inc. | -50.61 Million USD | 1280.582% |
| Alector, Inc. | -130.39 Million USD | 558.313% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 625.482% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 1252.62% |
| Zai Lab Limited | -334.62 Million USD | 278.59% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 284.452% |
| Aura Biosciences, Inc. | -76.4 Million USD | 882.116% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 354.696% |
| Immunic, Inc. | -93.61 Million USD | 738.379% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 539.757% |
| Veracyte, Inc. | -74.4 Million USD | 903.181% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 7885.748% |
| FibroGen, Inc. | -284.23 Million USD | 310.25% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 2378.13% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 8634.824% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 3273.2% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | -44.058% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 2749.519% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -1112.882% |
| TG Therapeutics, Inc. | 12.67 Million USD | -4615.901% |
| Galecto, Inc. | -38.34 Million USD | 1658.317% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 3267.598% |
| Fortrea Holdings Inc. | -3.4 Million USD | 17676.441% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 571.873% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 3532.307% |
| XBiotech Inc. | -24.55 Million USD | 2533.518% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 1027.013% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 1053.413% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 707.156% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 2889.0% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 1182.744% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 198.51% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 975.539% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 1049734.665% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 363.795% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 2783.725% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 371.994% |
| NexImmune, Inc. | -32.34 Million USD | 1947.612% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 11404.088% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 4354.617% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 84.885% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 2567.276% |
| Scopus BioPharma Inc. | -11.6 Million USD | 5247.355% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 611.652% |
| Ainos, Inc. | -13.77 Million USD | 4439.689% |
| Pluri Inc. | -20.88 Million USD | 2960.968% |
| Prothena Corporation plc | -147.02 Million USD | 506.453% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 624.804% |
| Celularity Inc. | -196.29 Million USD | 404.439% |
| Rallybio Corporation | -74.56 Million USD | 901.458% |
| Cue Biopharma, Inc. | -50.73 Million USD | 1277.93% |
| MeiraGTx Holdings plc | -84.02 Million USD | 811.199% |
| Omeros Corporation | -117.81 Million USD | 607.244% |
| Humacyte, Inc. | -110.77 Million USD | 639.466% |
| Immunocore Holdings plc | -55.28 Million USD | 1180.903% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 3422.948% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 2706.075% |
| Blueprint Medicines Corporation | -506.98 Million USD | 217.873% |
| CalciMedica, Inc. | -34.35 Million USD | 1839.381% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 983.042% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 522.615% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 460.458% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 310.976% |
| Pulmatrix, Inc. | -14.12 Million USD | 4331.988% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 1797.966% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 823.153% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 224.191% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 669.842% |
| Cytokinetics, Incorporated | -526.24 Million USD | 213.559% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 1757.005% |
| Nutriband Inc. | -5.48 Million USD | 10994.527% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 1578.474% |
| Vor Biopharma Inc. | -117.86 Million USD | 607.028% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 86.259% |
| Evogene Ltd. | -23.87 Million USD | 2602.613% |
| ProKidney Corp. | -35.46 Million USD | 1784.896% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 598.985% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 7717.199% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 192.91% |
| CorMedix Inc. | -46.33 Million USD | 1389.618% |
| BioLineRx Ltd. | -60.61 Million USD | 1085.909% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 687.356% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 1555.216% |
| Atai Life Sciences N.V. | -40.22 Million USD | 1585.678% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 840.977% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 891.302% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 304.523% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 2243.776% |
| MediciNova, Inc. | -8.57 Million USD | 7071.917% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 584.761% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 7233.948% |
| GeoVax Labs, Inc. | -25.96 Million USD | 2401.4% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 349.793% |
| Biomea Fusion, Inc. | -117.25 Million USD | 609.658% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 195.371% |
| Mereo BioPharma Group plc | -29.46 Million USD | 2128.097% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 490.174% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 385.441% |
| Absci Corporation | -110.56 Million USD | 640.491% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 2082.086% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 692.639% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 353.288% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -4143.106% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 409.698% |
| Allakos Inc. | -185.7 Million USD | 421.807% |
| Imunon, Inc. | -19.51 Million USD | 3162.258% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 713.961% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -463.029% |
| BioAtla, Inc. | -123.46 Million USD | 584.035% |
| NLS Pharmaceutics AG | -12.17 Million USD | 5009.609% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 3816.874% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 282.604% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 1717.362% |
| XOMA Corporation | -40.83 Million USD | 1563.591% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 686.629% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 604.248% |
| aTyr Pharma, Inc. | -50.38 Million USD | 1285.971% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 781.576% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 493.782% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 351.373% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 1801.64% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 7485.114% |
| Akari Therapeutics, Plc | -10 Million USD | 6071.213% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 887733.123% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -112.22% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 9066.362% |
| UroGen Pharma Ltd. | -102.24 Million USD | 684.483% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 659.586% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 7784.002% |
| Orgenesis Inc. | -55.36 Million USD | 1179.458% |
| Entera Bio Ltd. | -8.88 Million USD | 6822.905% |
| GH Research PLC | -35.58 Million USD | 1779.262% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 2967.558% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 872.211% |
| Xencor, Inc. | -126.08 Million USD | 573.958% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 15969.524% |
| Replimune Group, Inc. | -215.79 Million USD | 376.93% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 2910.044% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -23718.214% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 9066.362% |
| Portage Biotech Inc. | -75.33 Million USD | 893.213% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 7233.948% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 718.28% |
| OncoCyte Corporation | -27.78 Million USD | 2251.107% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 4553.973% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 5473.357% |
| Purple Biotech Ltd. | -19.88 Million USD | 3106.031% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 8614.019% |
| scPharmaceuticals Inc. | -54.81 Million USD | 1190.31% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 3513.653% |
| HilleVax, Inc. | -123.56 Million USD | 583.627% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 6012.724% |
| Tharimmune, Inc. | -9.31 Million USD | 6512.63% |
| Genprex, Inc. | -30.86 Million USD | 2036.455% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 353.3% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 2085.775% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 33635.297% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 11383.937% |
| OKYO Pharma Limited | -16.82 Thousand USD | 3551854.306% |
| Savara Inc. | -54.69 Million USD | 1192.543% |
| Curis, Inc. | -47.41 Million USD | 1360.412% |
| Daré Bioscience, Inc. | -30.16 Million USD | 2081.338% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 3969.185% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 10830.813% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 2104.357% |
| BeiGene, Ltd. | -881.7 Million USD | 167.777% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 2906.42% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 236.949% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 856.886% |
| Erasca, Inc. | -125.04 Million USD | 577.919% |
| bluebird bio, Inc. | -211.91 Million USD | 382.002% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 12050.792% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -256.467% |
| DBV Technologies S.A. | -72.72 Million USD | 921.713% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 12050.792% |
| Moderna, Inc. | -4.71 Billion USD | 112.677% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 1588.156% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 10595.241% |
| Molecular Templates, Inc. | -8.12 Million USD | 7455.97% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 1089.599% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 636.449% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 541.515% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 1347.102% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 522.543% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 410.586% |
| MacroGenics, Inc. | -9.05 Million USD | 6697.472% |
| RenovoRx, Inc. | -10.23 Million USD | 5940.491% |
| Adicet Bio, Inc. | -142.65 Million USD | 518.903% |
| Prime Medicine, Inc. | -198.13 Million USD | 401.615% |
| Aditxt, Inc. | -32.38 Million USD | 1945.533% |
| Adagene Inc. | -18.94 Million USD | 3254.161% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 8273.162% |
| Quantum-Si incorporated | -95.96 Million USD | 722.758% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 602.062% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 4199.386% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -351.598% |
| SciSparc Ltd. | -5.12 Million USD | 11767.298% |
| Vericel Corporation | -3.18 Million USD | 18880.61% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 497047.295% |
| Minerva Neurosciences, Inc. | -30 Million USD | 2091.641% |
| Generation Bio Co. | -126.61 Million USD | 571.992% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 919.853% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 824.872% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 327.969% |
| Invivyd, Inc. | -198.64 Million USD | 400.841% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 274.75% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 6979.571% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -2520.359% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 6152.248% |
| 2seventy bio, Inc. | -217.57 Million USD | 374.67% |
| ADMA Biologics, Inc. | -28.23 Million USD | 2216.219% |
| Clene Inc. | -49.5 Million USD | 1307.173% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 2781.314% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 1308.883% |
| GeoVax Labs, Inc. | -25.96 Million USD | 2401.4% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 282.158% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 1936.342% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -2530.277% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 704.908% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 899.421% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 471.63% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 197.161% |
| Evaxion Biotech A/S | -22.12 Million USD | 2801.012% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 840.189% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 398.698% |
| Trevena, Inc. | -40.28 Million USD | 1583.281% |
| Surrozen, Inc. | -43.04 Million USD | 1488.409% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 964.407% |
| Cingulate Inc. | -23.53 Million USD | 2639.198% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 8745.819% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 1599.245% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 7850.283% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 762.453% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 1075.099% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 1104.317% |
| Clearmind Medicine Inc. | -11.95 Million USD | 5098.724% |
| Kronos Bio, Inc. | -112.67 Million USD | 630.383% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 963.62% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 23562592.361% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 795.732% |
| Statera Biopharma, Inc. | -174.4 Million USD | 442.644% |
| ImmunityBio, Inc. | -583.19 Million USD | 202.47% |
| Korro Bio, Inc. | -81.17 Million USD | 836.213% |
| Kineta, Inc. | -14.09 Million USD | 4338.591% |
| BioVie Inc. | -32.12 Million USD | 1960.489% |
| Codexis, Inc. | -76.24 Million USD | 883.839% |
| Celularity Inc. | -196.29 Million USD | 404.439% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 378.563% |
| Celcuity Inc. | -63.77 Million USD | 1036.982% |
| Virax Biolabs Group Limited | -6.73 Million USD | 8974.964% |
| Cibus, Inc. | -267.62 Million USD | 323.295% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 1581.92% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 1768.758% |
| IN8bio, Inc. | -30 Million USD | 2091.532% |
| Kodiak Sciences Inc. | -260.49 Million USD | 329.413% |
| Annexon, Inc. | -134.23 Million USD | 545.182% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 610.049% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 1076.022% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 1994.493% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 263.151% |
| Eyenovia, Inc. | -27.26 Million USD | 2292.131% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -2667.815% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 111800.748% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 882.157% |
| Arcellx, Inc. | -70.69 Million USD | 945.38% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 1542.048% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 546.583% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 2089.543% |
| Moolec Science SA | -51.78 Million USD | 1253.914% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 1241.088% |
| Geron Corporation | -184.12 Million USD | 424.558% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 1523.736% |
| Royalty Pharma plc | 1.13 Billion USD | 47.34% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 539.553% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 6820.785% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 2913.127% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 448.109% |
| Humacyte, Inc. | -110.77 Million USD | 639.466% |
| Structure Therapeutics Inc. | -89.62 Million USD | 766.814% |
| 89bio, Inc. | -142.18 Million USD | 520.285% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 966.588% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 5858.88% |
| Genelux Corporation | -28.29 Million USD | 2211.881% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 2156.078% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 437.4% |
| Notable Labs, Ltd. | -11.26 Million USD | 5405.389% |
| Liquidia Corporation | -78.5 Million USD | 861.253% |
| Mustang Bio, Inc. | -51.6 Million USD | 1258.093% |
| Immunovant, Inc. | -259.33 Million USD | 330.434% |
| Quantum-Si incorporated | -95.96 Million USD | 722.758% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 920.326% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 3183.427% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 722.564% |
| Acasti Pharma Inc. | -12.85 Million USD | 4749.49% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 2760.979% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 3843.966% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 427.644% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 13992.75% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 4892.294% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 2126.378% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 1632.777% |
| PepGen Inc. | -78.62 Million USD | 860.053% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 2107.454% |
| United Therapeutics Corporation | 984.8 Million USD | 39.318% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 2784.632% |
| Solid Biosciences Inc. | -96.01 Million USD | 722.402% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 12572.154% |
| Immuneering Corporation | -53.47 Million USD | 1217.6% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 11847.505% |
| Silo Pharma, Inc. | -3.7 Million USD | 16248.343% |
| Belite Bio, Inc | -31.63 Million USD | 1989.223% |
| XOMA Corporation | -40.83 Million USD | 1563.591% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 1199.235% |
| Bionomics Limited | -15.49 Billion USD | 103.857% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 811.554% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 2149.59% |
| uniQure N.V. | -308.47 Million USD | 293.725% |
| Cassava Sciences, Inc. | -97.21 Million USD | 714.706% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 8273.162% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 584.16% |
| Forte Biosciences, Inc. | -31.47 Million USD | 1998.586% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 7386.279% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 2155.866% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 111800.748% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 2378.13% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 3725.108% |
| Altimmune, Inc. | -88.44 Million USD | 775.658% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 494.236% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 2149.59% |
| Compugen Ltd. | -18.75 Million USD | 3286.515% |
| Peak Bio, Inc. | -1259.26 USD | 47456463.261% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 1397.746% |
| Benitec Biopharma Inc. | -21.75 Million USD | 2847.455% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 276.392% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 820.398% |
| Zura Bio Limited | -60.36 Million USD | 1090.058% |
| PolyPid Ltd. | -23.86 Million USD | 2604.081% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 3898.621% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 820.398% |
| Instil Bio, Inc. | -156.08 Million USD | 482.863% |
| argenx SE | -295.05 Million USD | 302.54% |
| Immunome, Inc. | -106.8 Million USD | 659.518% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 1506.314% |
| Verona Pharma plc | -54.36 Million USD | 1199.154% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 698.095% |
| Shattuck Labs, Inc. | -87.29 Million USD | 784.551% |
| CervoMed Inc. | -2.17 Million USD | 27615.375% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 579.418% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 4587.827% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 1472.056% |
| Moolec Science SA | -51.78 Million USD | 1253.914% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 3456081.559% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 542.281% |
| AnaptysBio, Inc. | -163.61 Million USD | 465.238% |
| Design Therapeutics, Inc. | -66.86 Million USD | 993.78% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 834.025% |
| NeurAxis, Inc. | -14.62 Million USD | 4185.677% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 1677.528% |
| Lumos Pharma, Inc. | -34.03 Million USD | 1855.888% |
| Achilles Therapeutics plc | -69.66 Million USD | 957.818% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 698.095% |
| 180 Life Sciences Corp. | -19.93 Million USD | 3097.721% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -19761.772% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 23562592.361% |
| Nutriband Inc. | -5.48 Million USD | 10994.527% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 693.463% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 1329.45% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 875.186% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 1859.196% |
| MoonLake Immunotherapeutics | -36 Million USD | 1759.663% |
| Palisade Bio, Inc. | -12.3 Million USD | 4958.528% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 1518.666% |
| Beam Therapeutics Inc. | -132.52 Million USD | 550.926% |
| Neurogene Inc. | -36.31 Million USD | 1745.508% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 465.694% |
| AEON Biopharma, Inc. | -52.55 Million USD | 1237.071% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 708.882% |
| Sesen Bio, Inc. | -19.88 Million USD | 3105.426% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 934.822% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 4875.483% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 234.583% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 635.646% |
| Athira Pharma, Inc. | -117.67 Million USD | 607.851% |
| Vaccinex, Inc. | -20.25 Million USD | 3050.96% |
| HCW Biologics Inc. | -24.99 Million USD | 2490.943% |
| XOMA Corporation | -40.83 Million USD | 1563.591% |
| Nektar Therapeutics | -276.05 Million USD | 316.477% |
| Arvinas, Inc. | -367.3 Million USD | 262.701% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 887733.123% |
| Merus N.V. | -154.93 Million USD | 485.7% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 713.375% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 2004.091% |
| Rezolute, Inc. | -68.45 Million USD | 972.93% |
| Clene Inc. | -49.5 Million USD | 1307.173% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 3974.608% |
| BeyondSpring Inc. | -21.02 Million USD | 2942.191% |
| Synlogic, Inc. | -57.28 Million USD | 1143.258% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 5121.418% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 5620.035% |
| Peak Bio, Inc. | -1259.26 USD | 47456463.261% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 1699.227% |
| Krystal Biotech, Inc. | 10.93 Million USD | -5366.511% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 517.612% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 283.818% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 13037.942% |
| MannKind Corporation | -11.93 Million USD | 5105.855% |
| Ikena Oncology, Inc. | -68.16 Million USD | 976.682% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 2943.678% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 743.043% |
| Gossamer Bio, Inc. | -179.81 Million USD | 432.337% |
| CohBar, Inc. | -11.96 Million USD | 5095.762% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 2417.353% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 2082.086% |
| Legend Biotech Corporation | -518.25 Million USD | 215.31% |
| Mural Oncology plc | -207.44 Million USD | 388.073% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 581.488% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 3367.403% |
| Disc Medicine, Inc. | -76.42 Million USD | 881.901% |
| Champions Oncology, Inc. | -7.27 Million USD | 8313.29% |
| REGENXBIO Inc. | -263.49 Million USD | 326.798% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 5730.781% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 1357.971% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 1673.312% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 696.626% |
| Vaxart, Inc. | -82.46 Million USD | 824.67% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -178948.906% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 1691.793% |
| Cellectis S.A. | -101.05 Million USD | 691.337% |
| Longeveron Inc. | -21.41 Million USD | 2890.823% |
| Repare Therapeutics Inc. | -93.79 Million USD | 737.126% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 211.497% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 939.69% |
| Revolution Medicines, Inc. | -436.36 Million USD | 236.949% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 9194.491% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 2038.746% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 961.926% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 1023.189% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 6191.112% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 83.49% |
| Denali Therapeutics Inc. | -145.22 Million USD | 511.502% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 497047.295% |
| Veru Inc. | -93.15 Million USD | 741.526% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 2310.955% |
| Cingulate Inc. | -23.53 Million USD | 2639.198% |
| Passage Bio, Inc. | -102.06 Million USD | 685.525% |
| Context Therapeutics Inc. | -23.96 Million USD | 2593.714% |
| Exicure, Inc. | -16.91 Million USD | 3633.162% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 416.329% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 1682.457% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 9283.482% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 423.59% |
| Nuvalent, Inc. | -126.21 Million USD | 573.462% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 5782.946% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 787.852% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 2056.518% |
| OmniAb, Inc. | -50.61 Million USD | 1280.582% |
| Anew Medical, Inc. | 1.34 Million USD | -44294.02% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 3824.519% |
| Lipocine Inc. | -16.35 Million USD | 3754.574% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 1000.08% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 1038.514% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 1516.32% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 1345.854% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 3113.459% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 210.362% |
| Ocugen, Inc. | -63.07 Million USD | 1047.397% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 724.242% |
| Q32 Bio Inc. | -112.96 Million USD | 629.031% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 3576.03% |
| Alumis Inc. Common Stock | -154.99 Million USD | 485.565% |
| Equillium, Inc. | -13.33 Million USD | 4581.432% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 1089.96% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 7581.363% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 3270.08% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 1111.474% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 621.797% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 3351.717% |
| Dominari Holdings Inc. | -22.88 Million USD | 2711.655% |
| Edesa Biotech, Inc. | -8.37 Million USD | 7236.009% |
| vTv Therapeutics Inc. | -20.25 Million USD | 3051.106% |
| Bio-Techne Corporation | 168.1 Million USD | -255.492% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 269.73% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -363.784% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 590.511% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 1675.157% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 630.529% |
| Nkarta, Inc. | -117.5 Million USD | 608.591% |
| BioCardia, Inc. | -11.57 Million USD | 5264.627% |
| Iterum Therapeutics plc | -38.37 Million USD | 1657.424% |